Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Taxane-Induced Peripheral Neuropathy Clear all
Recruiting Not applicable Interventional

Cryocompression for CIPN

NCT07064798
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Taxane-Induced Peripheral Neuropathy, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Paxman Limb Cryocompression System
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Early Phase 1 Interventional

BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients

NCT05291286
View directory record Official record
Conditions
Neuropathy;Peripheral, Chemotherapy-induced Peripheral Neuropathy
Interventions
BXQ-350, Placebo
Drug · Other
Lead sponsor
Bexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Cincinnati, Ohio • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Suspended Phase 2 Interventional

Vitamin D Supplementation on Reported Rates of Taxane-Induced Neuropathy

NCT05259527
View directory record Official record
Conditions
Neuropathic Pain
Interventions
Ergocalciferol Capsules, Cholecalciferol Capsules
Drug · Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional

A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients

NCT02129686
View directory record Official record
Conditions
Taxane-induced Peripheral Neuropathy, Chemotherapy-induced Peripheral Neuropathy (CIPN), Early-Stage Breast Carcinoma, Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
Immediate Acupuncture Group, Delayed Acupuncture Group
Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

NCT02610439
View directory record Official record
Conditions
Breast Carcinoma, Neuropathy
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated No phase listed Observational

Risk Prediction of Taxane Chemotherapy-Induced Peripheral Neuropathy

NCT04932031
View directory record Official record
Conditions
Breast Cancer, Chemotherapy-induced Peripheral Neuropathy, Aging
Interventions
Not listed
Lead sponsor
Sapere Bio
Industry
Eligibility
18 Years and older · Female only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Not applicable Interventional

Heading Off Peripheral Neuropathy With Exercise

NCT00869804
View directory record Official record
Conditions
Peripheral Nervous System Disorders, Breast Neoplasms, Chemotherapy
Interventions
Aerobic/ Resistance Exercise Intervention, Attention control
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 3 Interventional

Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral Neuropathy

NCT05642611
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Cryocompression Therapy, Pneumatic Compression Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
777 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
36
States / cities
Birmingham, Alabama • Martinez, California • Fairfield, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Completed No phase listed Observational

Objective Evaluation of Paclitaxel/Docetaxel-induced Neuropathy in Breast Cancer Patients

NCT03872141
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Induced Peripheral Neuropathy, Paclitaxel Induced Neuropathy
Interventions
Quantitative measures of reduction in Chemotherapy Induced Neuropathy (CIPN) and Cognitive Impairment (CICI) in patients with stage I-III breast cancer
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
13 participants
Timeline
2017 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

NCT00267007
View directory record Official record
Conditions
Peripheral Neuropathy, Chemotherapy-induced
Interventions
PROCRIT 40,000 IU QW, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
28
States / cities
Mobile, Alabama • Little Rock, Arkansas • Alhambra, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Jul 22, 2026, 10:53 AM EDT
Withdrawn Phase 1 Interventional

L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

NCT02215083
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
L-glutamine
Dietary Supplement
Lead sponsor
Eastern Regional Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jul 22, 2026, 10:53 AM EDT
Not listed Not applicable Interventional

Home-Based Physical Activity Intervention for Taxane-Induced CIPN

NCT04621721
View directory record Official record
Conditions
Breast Cancer Female, Chemotherapy-induced Peripheral Neuropathy, Gait Disorders, Neurologic, Balance; Distorted, Muscle Weakness
Interventions
Gait/balance & resistive exercise
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
21 Years and older · Female only
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients

NCT00659269
View directory record Official record
Conditions
Cancer
Interventions
Multivitamin (MV), Multivitamin + Vitamin B12 + Vitamin B6, Chemotherapy
Dietary Supplement · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
5
States / cities
Albuquerque, New Mexico • Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 25, 2016 · Synced Jul 22, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

The Effect of Acupuncture on Nerve Pain Caused by Taxane (Chemotherapy) Treatment

NCT05458284
View directory record Official record
Conditions
Breast Cancer, Taxane-Induced Peripheral Neuropathy
Interventions
Real Acupuncture, Sham Acupuncture
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT04001829
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Docetaxel, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
485
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 310 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Not applicable Interventional

Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

NCT01050075
View directory record Official record
Conditions
Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
acupuncture therapy, questionnaire administration, management of therapy complications
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Duarte, California • Pasadena, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 1Phase 2 Interventional

Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG

NCT01815346
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Questionnaires, Hand Function and Balance Tests
Procedure · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer

NCT03139435
View directory record Official record
Conditions
Peripheral Neuropathy, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Biopsy, Questionnaire Administration, Ultrasound Tomography
Procedure · Other · Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 7, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Recruiting Phase 2 Interventional

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

NCT07109817
View directory record Official record
Conditions
Breast Cancer, Peripheral Neuropathy
Interventions
Desloratodine, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 10:53 AM EDT
Active, not recruiting Phase 2 Interventional

NIAGEN and Persistent Chemotherapy-Induced Peripheral Neuropathy

NCT04112641
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Nicotinamide riboside, Placebo capsules
Drug
Lead sponsor
Donna Hammond, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 29, 2025 · Synced Jul 22, 2026, 10:53 AM EDT
Completed Not applicable Interventional Results available

The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL

NCT03873272
View directory record Official record
Conditions
CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Cryotherapy, Compression Therapy, Loose glove/sock
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Phase 2 Interventional Results available

Cannabinoids for Taxane Induced Peripheral Neuropathy

NCT03782402
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Cannabinoids
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 60 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Jul 22, 2026, 10:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer

NCT02549534
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Axon Reflexes, Axon Flares, Self-Reported Signs & Symptoms of CIPN
Procedure
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jul 22, 2026, 10:53 AM EDT
Terminated Not applicable Interventional

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

NCT05368428
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Chemotherapy-Induced Peripheral Neuropathy, Early Stage Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Transcutaneous Electrical Nerve Stimulation
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 10:53 AM EDT